MDM2 and lung carcinoma: In this meta-analysis was shown no association MDM2(rs2279744) polymorphism with lung cancer (G versus T:OR = 0.86, 95 % CI 0.71–1.03, p = 0.1; GG versus TT:OR = 0.86, 95 % CI 0.71–1.03, p = 0.1; GG+GT versus TT:OR = 0.90, 95 % CI 0.79–1.02, p = 0.5; GG versus GT+TT:OR = 1.10, 95 % CI 0.94–1.22, p = 0.276).